CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab

Background: The kinetics of B cell repopulation in MS patients treated with Ocrelizumab is highly variable, suggesting that a fixed dosage and time scheduling might be not optimal. We aimed to investigate whether B cell repopulation kinetics influences clinical and radiological outcomes and whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbadessa, Gianmarco, Miele, Giuseppina, Cavalla, Paola, Valentino, Paola, Marfia, Girolama Alessandra, Signoriello, Elisabetta, Landi, Doriana, Bosa, Chiara, Vercellino, Marco, De Martino, Antonio, Missione, Rosanna, Sparaco, Maddalena, Lavorgna, Luigi, Lus, Giacomo, Bonavita, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346113/
https://www.ncbi.nlm.nih.gov/pubmed/34360456
http://dx.doi.org/10.3390/ijerph18158163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346113/
https://www.ncbi.nlm.nih.gov/pubmed/34360456
http://dx.doi.org/10.3390/ijerph18158163

Ejemplares similares